StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) stock

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

First Tracks Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$23.85M-39.3%
Q2 FY2026Jun 30, 2026$25.64M-38.2%
Q1 FY2026Mar 31, 2026$33.96M–
Q3 FY2025Sep 30, 2025$33.32M–
Q2 FY2025Jun 30, 2025$39.27M–
Q1 FY2025Mar 31, 2025$41.47M–

More First Tracks Biotherapeutics figures

See a number that looks wrong?